Indaptus Therapeutics (INDP) Other Non-Current Assets (2020 - 2025)
Indaptus Therapeutics (INDP) posted quarterly Other Non-Current Assets of $392572.0 for Q3 2025, down 22.22% year-over-year from $504728.0 in Q3 2024, and little changed quarter-over-quarter from $392572.0 in Q2 2025.
Indaptus Therapeutics (INDP) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Indaptus Therapeutics' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $392572.0 for Q3 2025.
- In Q3 2025, Other Non-Current Assets fell 22.22% year-over-year to $392572.0; the TTM figure through Sep 2025 stood at $392572.0 (down 22.22% YoY), while the FY2024 annual figure was $638251.0, down 15.43% from the prior year.
- Other Non-Current Assets for Q3 2025 stood at $392572.0, roughly flat from $392572.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.7 million in Q1 2021, with the low at $16477.0 in Q4 2021.
- The 5-year median for Other Non-Current Assets is $648650.0 (2022), against an average of $752835.8.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets slumped 99.56% in 2022, then jumped 4480.49% in 2023.
- Indaptus Therapeutics' Other Non-Current Assets stood at $16477.0 in 2021, then jumped by 4380.49% to $738251.0 in 2022, then gained by 2.23% to $754728.0 in 2023, then declined by 15.43% to $638251.0 in 2024, then slumped by 38.49% to $392572.0 in 2025.
- Business Quant data shows INDP's Other Non-Current Assets at $392572.0 in Q3 2025, $392572.0 in Q2 2025, and $392572.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 392,572.00 |
| Jun 30, 2025 | 392,572.00 |
| Mar 31, 2025 | 392,572.00 |
| Dec 31, 2024 | 638,251.00 |
| Sep 30, 2024 | 504,728.00 |
| Jun 30, 2024 | 504,728.00 |
| Mar 31, 2024 | 504,728.00 |
| Dec 31, 2023 | 754,728.00 |
| Sep 30, 2023 | 754,728.00 |
| Jun 30, 2023 | 754,728.00 |
| Mar 31, 2023 | 754,728.00 |
| Dec 31, 2022 | 738,251.00 |
| Sep 30, 2022 | 754,728.00 |
| Jun 30, 2022 | 659,049.00 |
| Mar 31, 2022 | 16,477.00 |
| Dec 31, 2021 | 16,477.00 |
| Jun 30, 2021 | 1.30 Mn |
| Mar 31, 2021 | 3.72 Mn |
| Dec 31, 2020 | 44,445.00 |